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Abstract
Mining gene expression profiles has proven valuable for identifying signatures serving as surrogates of cancer phenotypes.
However, the similarities of such signatures across different cancer types have not been strong enough to conclude that
they represent a universal biological mechanism shared among multiple cancer types. Here we present a computational
method for generating signatures using an iterative process that converges to one of several precise attractors defining
signatures representing biomolecular events, such as cell transdifferentiation or the presence of an amplicon. By analyzing
rich gene expression datasets from different cancer types, we identified several such biomolecular events, some of which
are universally present in all tested cancer types in nearly identical form. Although the method is unsupervised, we show
that it often leads to attractors with strong phenotypic associations. We present several such multi-cancer attractors,
focusing on three that are prominent and sharply defined in all cases: a mesenchymal transition attractor strongly
associated with tumor stage, a mitotic chromosomal instability attractor strongly associated with tumor grade, and a
lymphocyte-specific attractor.
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Introduction
Despite their type-specific features, cancers share some common
traits, or ‘‘hallmarks,’’ related to, e.g., the abilities of some cancer
cells to divide uncontrollably or to invade surrounding tissues [1].
Furthermore, it has been recognized that gene expression
signatures resulting from analysis of cancer datasets can serve as
surrogates of cancer phenotypes [2]. Therefore, it is reasonable to
hypothesize that computational analysis of rich biomolecular
cancer datasets may reveal signatures that are shared across many
cancer types and are associated with specific cancer phenotypes.
Such rich datasets become publicly available at an increasing rate
from many sources, such as The Cancer Genome Atlas (TCGA).
However, attempts to identify any such robust ‘‘bioinformatic
hallmarks’’ of cancer have so far been largely unsuccessful.
Gene signatures may occasionally be found to exhibit similar-
ities across multiple cancer types. However, to our knowledge no
algorithm has ever produced a set of nearly identical signatures
after independently and separately analyzing datasets from
different cancer types.
There are various ways by which modules of co-expressed genes
can be identified from rich datasets, some of which may be within
the context of regulatory network discovery [3]. Clustering
approaches can classify a selected set of genes into subsets each
of which contains mutually related genes. Related techniques can
also be used to classify samples into cancer subtypes [4–6], each
characterized by a set of characteristic genes. One of the most
powerful computational approaches for this task has been
nonnegative matrix factorization (NMF) [7] combined with
consensus clustering [8], resulting in successful subtype identifica-
tion in several types of cancer.
The main objective addressed by techniques such as NMF is to
reduce dimensionality by identifying a number of metagenes
jointly representing the gene expression dataset as accurately as
possible, in lieu of the whole set of individual genes. Each
metagene in NMF is defined as a positive linear combination of
the individual genes, so that its expression level is an accordingly
weighted average of the expression levels of the individual genes.
The identity of each resulting metagene is influenced by the
presence of other metagenes within the objective of overall
dimensionality reduction achieved by joint optimization.
By contrast, if the aim is exclusively to identify metagenes as
surrogates of biomolecular events, then a fully unconstrained
algorithm should be devised, without any effort to achieve
dimensionality reduction, classification, mutual exclusivity, or-
thogonality, regulatory interaction inference, etc.
We can consider, for example, a hypothetical case in which we
have found a cluster consisting of a number of co-expressed genes
in a rich gene expression dataset. We may wish to scrutinize and
‘‘sharpen’’ this co-expression trying to identify the ‘‘heart’’ (core) of
the genes that are most strongly co-expressed in that case. In the
absence of a defining phenotype, we can continue applying an
unsupervised methodology, as follows: We can first define a
consensus metagene from the average expression levels of all genes
in the cluster, and rank all the individual genes in terms of their
association (defined numerically by some form of correlation) with
that metagene. We can then replace the member genes of the
cluster with an equal number of the top-ranked genes. Some of the
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original genes may naturally remain as members of the cluster, but
some may be replaced, as this process will ‘‘attract’’ some other
genes that are more strongly correlated with the cluster. We can
now define a new metagene defined by the average expression
levels of the genes in the newly defined cluster, and re-rank all the
individual genes in terms of their association with that new
metagene; and so on. It is intuitively reasonable to expect that this
iterative process will eventually converge to a cluster that contains
precisely the genes that are most associated with the metagene of
the same cluster, so that any other individual genes will be less
strongly associated with the metagene. We can think of this
particular cluster defined by the convergence of this iterative
process as an ‘‘attractor,’’ i.e., a module of co-expressed genes to
which many other gene sets with close but not identical
membership will converge using the same computational meth-
odology.
The above description represents a simplified conceptual
introduction of the computational methodology presented in this
paper. Rather than using the average of the expression values in
gene clusters of a particular size, the ‘‘attractors’’ are metagenes
defined as weighted averages of all genes where each individual
gene has a nonnegative weight, just like the metagenes defined
using NMF [7]. We found that, given a rich (loosely defined as
containing at least 200 samples) dataset represented by a gene
expression matrix, such metagenes can be naturally identified as
stable and precise attractors using a simple iterative approach. We
experimentally verified these nice convergence properties without
any exception after trying numerous times the method described
in this paper on such rich datasets.
This methodology is totally unsupervised, as it does not make
use of any phenotypic association. As we show in this paper,
however, once identified, a metagene attractor is likely to be found
associated with a phenotype.
We found that several attractor metagenes are present in nearly
identical form in multiple cancer types. This provides an
additional opportunity to combine the powers of a large number
of rich datasets to focus, at an even sharper level, on the core genes
of the underlying mechanism. For example, this methodology can
precisely point to the causal (driver) oncogenes within amplicons to
be among very few candidate genes. Importantly, this can be done
from rich gene expression data, which already exist in abundance,
without making any use of sequencing data.
We identified several attractors, each of which has the potential
to lead to corresponding testable biological hypotheses after
scrutinizing their top-ranked genes and finding a putative
underlying mechanism. For the purposes of this paper we present
the general methodology for the benefit of the research
community together with a listing of the attractors in six datasets
from three cancer types (ovarian, colon, breast).
Here, we focus on a few interesting cancer-associated attractors
that we found present in multiple cancer types. Particular
emphasis is given to what we consider to be three key
‘‘bioinformatic hallmarks’’ of cancer, related to the ability of
cancer cells to invade surrounding tissues; to divide uncontrollably;
and the ability of the organism to recruit the immune system to
fight cancer: a tumor stage-associated mesenchymal transition
attractor, a tumor grade-associated mitotic chromosomal instabil-
ity (mitotic CIN) attractor, and a lymphocyte-specific attractor.
Results
Derivation of Attractor Metagenes
Given a nonnegative measure J(Gi,Gj) of pairwise association
between genes Gi and Gj , we define an attractor metagene
M~
P
i wiGi to be a linear combination of the individual genes
with weights wi~J(Gi,M). The association measure J is assumed
to have minimum possible value 0 and maximum possible value 1,
so the same is true for the weights. It is also assumed to be scale-
invariant, therefore it is not necessary for the weights to be
normalized so that they add to 1, and the metagenes can still be
thought of as expressing a normalized weighted average of the
expression levels of the individual genes. See Materials and
Methods for the choice of the measure J .
According to this definition, the genes with the highest weights
in an attractor metagene will have the highest association with the
metagene (and, by implication, they will tend to be highly
associated among themselves) and so they will often represent a
biomolecular event reflected by the co-expression of these top
genes. This can happen, e.g., when a biological mechanism is
activated, or when a copy number variation (CNV), such as an
amplicon, is present, in some of the samples included in the
expression matrix. In the following we use the term ‘‘attractor’’ for
simplicity to refer to an attractor metagene, and the term ‘‘top
genes’’ to refer to the genes with the highest weights in the
attractor. The definition of an attractor metagene can readily be
generalized to include features other than gene expression, such as
methylation values. It can also be used in datasets of any objects
(not necessarily genes) characterized by any type of feature vectors,
with applications in other disciplines, such as social and economic
sciences.
The computational problem of identifying attractor metagenes
given an expression matrix can be addressed heuristically using a
simple iterative process: Starting from a particular seed (or
‘‘attractee’’) metagene M, a new metagene is defined in which the
new weights are wi~J(Gi,M). The same process is then repeated
in the next iteration resulting in a new set of weights, and so forth.
In all gene expression datasets that we tried we found that this
process converges to a limited number of stable attractors. Each
attractor is defined by a precise set of weights, which are reached
with high accuracy typically within 10 or 20 iterations.
This algorithmic behavior with nice convergence properties is
not surprising, because if a metagene represents co-expressed
Author Summary
Cancer is known to be characterized by several unifying
biological capabilities or ‘‘hallmarks.’’ However, attempts
to computationally identify patterns, such as gene expres-
sion signatures, shared across many different cancer types
have been largely unsuccessful. A typical approach has
been to classify samples into mutually exclusive subtypes,
each of which is characterized by a particular gene
signature. Although occasional similarities of such signa-
tures in different cancer types exist, these similarities have
not been sufficiently strong to conclude that they reflect
the same biological event. By contrast, we have developed
a computational methodology that has identified some
signatures of co-expressed genes exhibiting remarkable
similarity across many different cancer types. These
signatures appear as stable ‘‘attractors’’ of an iterative
computational procedure that tends to collect mutually
associated genes, so that its convergence can point to the
core (‘‘heart’’) of the underlying biological co-expression
mechanism. One of these ‘‘pan-cancer’’ attractors corre-
sponds to a transdifferentiation of cancer cells empower-
ing them with invasiveness and motility. Another repre-
sents a mitotic chromosomal instability of cancer cells. A
third attractor is lymphocyte-specific.
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genes, then the next iteration will naturally ‘‘attract’’ other
similarly co-expressed genes, and so forth, until there are no other
genes more associated with the top genes than those genes
themselves. Furthermore, the set of the few genes with the highest
weight are likely to represent the ‘‘heart’’ (core) of the underlying
biomolecular event. In support of this concept, the association of
any of the top-ranked individual genes with the attractor metagene
is consistently and significantly higher than the pairwise associa-
tion between any of these genes, suggesting that the set of these top
genes jointly comprise a proxy representing a biomolecular event
better than each of the individual genes would.
Indeed, related versions of the signatures identified by attractors
in this paper have been previously identified in various contexts in
individual cancer types, often intermingled with additional genes.
However, the contribution of our work is that these signatures are
found as pan-cancer biomolecular events, sharply pointing to the
underlying mechanism. Therefore the top genes of the attractors
will be appropriate for being used as biomarkers or for
understanding the underlying biology. For example, one of the
attractors that we identified (the ‘‘mitotic chromosomal instability’’
attractor, described below) has previously been found in approx-
imate forms among sets of genes described generally [9] as
‘‘proliferation’’ or ‘‘cell cycle related’’ markers, while the actual
attractor points much more sharply to particular elements in the
structure of the kinetochore-microtubule interface.
A reasonable implementation of an ‘‘exhaustive’’ search of
attractor metagenes is to start from each individual gene as a seed
(‘‘attractee’’) assigning a weight of 1 to that gene, and 0 to all the
other genes. Each gene participating in a particular co-expression
event will then lead to the same attractor when used as attractee.
The computational implementation of the algorithm is described
in Materials and Methods. We note that a dual method can be
used to identify attractor ‘‘metasamples’’ as representatives of
subtypes, and we can also combine such metasamples with the
attractor metagenes in various ways to achieve biclustering, but
this topic is not examined in this paper.
We analyzed six datasets, two from ovarian cancer, two from
breast cancer and two from colon cancer (Supplementary Text
S1). In each case, we identified general (Supplementary Table S1)
and genomically localized (Supplementary Table S2) attractors
and we found that many among them appear in similar forms in
all six datasets using particular merging and ranking criteria in
each case (Materials and Methods and Supplementary Text S1).
Following are descriptions of some of our results, starting with the
three strongest multi-cancer attractors.
Mesenchymal Transition Attractor Metagene
This attractor contains mostly epithelial-mesenchymal transition
(EMT)-associated genes. Table 1 provides a listing of the top 100
genes based on their average mutual information (Materials and
Methods) with their corresponding attractor metagenes.
The consistency of the attractor is established by the fact
(Supplementary Table S1) that there are many genes (COL5A2,
COL1A2, SPARC, CTSK, FBN1, VCAN, AEBP1, SERPINF1)
that are among the top 50 genes in the attractors of all six datasets.
Table 1. Top 100 genes of the mesenchymal transition
attractor based on six datasets.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
1 COL5A2 0.814 51 SULF1 0.505
2 VCAN 0.775 52 LOXL1 0.502
3 SPARC 0.766 53 PRRX1 0.502
4 THBS2 0.758 54 PPAPDC1A 0.499
5 FBN1 0.749 55 COL10A1 0.498
6 COL1A2 0.749 56 ITGA11 0.495
7 COL5A1 0.747 57 NTM 0.494
8 FAP 0.734 58 MXRA8 0.494
9 AEBP1 0.711 59 FIBIN 0.493
10 CTSK 0.709 60 WISP1 0.483
11 COL3A1 0.688 61 RCN3 0.483
12 COL1A1 0.683 62 TNFAIP6 0.481
13 SERPINF1 0.674 63 ECM2 0.480
14 COL6A3 0.669 64 HTRA1 0.480
15 CDH11 0.663 65 EFEMP2 0.478
16 GLT8D2 0.658 66 MXRA5 0.474
17 LUM 0.654 67 ACTA2 0.472
18 MMP2 0.654 68 LOX 0.470
19 DCN 0.650 69 ITGBL1 0.466
20 CCDC80 0.637 70 PMP22 0.465
21 POSTN 0.631 71 P4HA3 0.464
22 CTHRC1 0.616 72 PTRF 0.463
23 ADAM12 0.613 73 CALD1 0.460
24 COL6A2 0.608 74 HEG1 0.458
25 MSRB3 0.608 75 NEXN 0.455
26 OLFML2B 0.607 76 NID2 0.455
27 INHBA 0.600 77 TAGLN 0.455
28 FSTL1 0.600 78 FAM26E 0.452
29 SFRP2 0.596 79 ZNF521 0.452
30 SNAI2 0.577 80 SFRP4 0.451
31 CRISPLD2 0.574 81 PALLD 0.450
32 PCOLCE 0.571 82 OLFML1 0.447
33 PDGFRB 0.567 83 FILIP1L 0.447
34 BGN 0.565 84 TIMP3 0.445
35 COL12A1 0.560 85 SPON2 0.443
36 ANGPTL2 0.555 86 SPOCK1 0.443
37 COPZ2 0.553 87 COL8A2 0.441
38 CMTM3 0.549 88 GPC6 0.438
39 ASPN 0.547 89 PDPN 0.437
40 FN1 0.545 90 GFPT2 0.436
41 CNRIP1 0.540 91 LHFP 0.436
42 FNDC1 0.538 92 GREM1 0.436
43 LRRC15 0.533 93 TGFB1I1 0.435
44 COL11A1 0.529 94 C1S 0.433
45 ANTXR1 0.528 95 EDNRA 0.432
46 RAB31 0.527 96 GAS1 0.431
47 FRMD6 0.524 97 NOX4 0.431
48 TSHZ3 0.520 98 FBLN2 0.428
49 THY1 0.519 99 TCF4 0.428
Table 1. Cont.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
50 NNMT 0.519 100 NUAK1 0.427
doi:10.1371/journal.pcbi.1002920.t001
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The corresponding P value is less than 1027 by permutation test
(Materials and Methods). Similar results are found in other solid
cancer types in all cases that we tried.
This is a stage-associated attractor, in which the signature is
significantly present only when a particular level of invasive stage,
specific to each cancer type, has been reached. Supplementary
Table S3 demonstrates this phenomenon in three cancer datasets
from different types (breast, ovarian and colon) that were
annotated with clinical staging information, by providing a listing
of differentially expressed genes, ranked by fold change, when
ductal carcinoma in situ (DCIS) progresses to invasive ductal
carcinoma; ovarian cancer progresses to stage III; and colon
cancer progresses to stage II. In all three cases, the attractor is
highly enriched among the top genes. Specifically, among the top
100 differentially expressed genes, the number of attractor genes
included in Table 1 is 47 in breast cancer, 42 in ovarian cancer
and 37 in colon cancer. The corresponding P values are 2610293,
4610280 and 8610278, respectively.
This attractor has been previously identified with remarkable
accuracy as representing a particular kind of mesenchymal
transition of cancer cells present in all types of solid cancers tested
leading to a published list of top 64 genes [10,11]. This list was
generated using a supervised algorithm using association with
tumor stage. Indeed 52 of these top 64 genes also appear in Table 1
(P,102114), and furthermore all top 19 genes of Table 1 are
among the 64. We found that most of the genes of the signature
were expressed by the cancer cells themselves, and not by the
surrounding stroma, at least in a neuroblastoma xenograft model
that we tried [11]. We also found that the signature is associated
with prolonged time to recurrence in glioblastoma [12]. Related
versions of the same signature were previously found to be
associated with resistance to neoadjuvant therapy in breast cancer
[13]. These results are consistent with the finding that EMT
induces cancer cells to acquire stem cell properties [14]. It has
been hypothesized that EMT is a key mechanism for cancer cell
invasiveness and motility [15–17]. The attractor, however, appears
to represent a more general phenomenon of transdifferentiation
present even in nonepithelial cancers such as neuroblastoma,
glioblastoma and Ewing’s sarcoma.
Although similar signatures are often labeled as ‘‘stromal,’’
because they contain many stromal markers such as a-SMA and
fibroblast activation protein, the fact that most of the genes of the
signature were expressed by xenografted cancer cells [11], and not
by mouse stromal cells, suggests that this particular attractor of
coordinately expressed genes represents cancer cells having
undergone a mesenchymal transition. The signature may indicate
a non-fibroblastic transition, as occurs in glioblastoma, in which
case collagen COL11A1 is not co-expressed with the other genes of
the attractor. We have hypothesized that a full fibroblastic
transition of the cancer cells occurs when cancer cells encounter
adipocytes [11], in which case they may well assume the duties of
cancer-associated fibroblasts (CAFs) in some tumors [1]. In that
case, the best proxy of the signature [10] is COL11A1 and the
strongly co-expressed genes THBS2 and INHBA. Indeed, the 64
genes of the previously identified signature were found from multi-
cancer analysis [10] as the genes whose expression is consistently
most associated with that of COL11A1.
The only EMT-inducing transcription factor found upregulated
in the xenograft model [11] is SNAI2 (Slug), and it is also the one
most associated with the signature in publicly available datasets.
We also found that the microRNAs most highly associated with
this attractor are miR-214, miR-199a, and miR-199b. Interest-
ingly, miR-214 and miR-199a were found to be jointly regulated
by another EMT-inducing transcription factor, TWIST1 [18].
The expression of the mesenchymal transition attractor
indicates that the tumor is actively invasive at the specific sample
site, so its prognostic value is cancer type and stage specific. As an
example, we analyzed an oral squamous cell carcinoma dataset
deposited in the Gene Expression Omnibus (GEO) under
accession number GSE25104. The corresponding Kaplan-Meier
survival curve (P=0.0066) is shown in Figure 1.
Mitotic CIN Attractor Metagene
This attractor contains mostly kinetochore-associated genes.
Table 2 provides a listing of the top 100 genes based on their
average mutual information (Materials and Methods) with their
corresponding attractor metagenes, starting from CENPA, which
encodes for a histone H3-like centromeric protein.
The consistency of the attractor is established by the fact
(Supplementary Table S1) that there are many genes (CENPA,
DLGAP5, KIF2C, CCNB2, MELK, CCNA2, KIF20A, HJURP,
NUSAP1, BUB1, TTK, KIF11, NCAPH) that are among the top
50 genes in the attractors of all six datasets. The corresponding P
value is less than 1027 by permutation test (Materials and
Methods). Similar results are found in other solid cancer types in
all cases that we tried.
Contrary to the stage-associated mesenchymal transition
attractor, this is a grade-associated attractor, in which the
signature is significantly present only when an intermediate level
of tumor grade is reached. Supplementary Table S4 demonstrates
this phenomenon in three cancer datasets from different types
(breast, ovarian and bladder) that were annotated with tumor
grade information, by providing a listing of differentially expressed
genes, ranked by fold change, when grade G2 is reached. In all
three cases, the attractor is highly enriched among the top genes.
Specifically, among the top 100 differentially expressed genes, the
number of attractor genes included Table 2 is 40 in breast cancer,
38 in ovarian cancer and 27 in colon cancer. The corresponding P
Figure 1. Kaplan-Meier curves of mesenchymal transition
attractor metagene in oral squamous cell carcinoma dataset.
Gene expression data from 57 patients (GSE25104) were divided into
two groups: high mesenchymal transition metagene level and low
mesenchymal transition metagene level depending on whether the
metagene expression value exceeding the mean of the 57 patients. The
P value of the association was determined by log-rank test.
doi:10.1371/journal.pcbi.1002920.g001
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values are 4610274, 3610269 and 3610249, respectively.
Consistently, a similar ‘‘gene expression grade index’’ signature
[19] was previously found differentially expressed between
histologic grade 3 and histologic grade 1 breast cancer samples.
Furthermore, that same signature [19] was found capable of
reclassifying patients with histologic grade 2 tumors into two
groups with high versus low risks of recurrence.
This attractor is associated with chromosomal instability (CIN),
as evidenced from the fact that another similar gene set comprising
a ‘‘signature of chromosomal instability’’ [20] was previously
derived from multiple cancer datasets purely by identifying the
genes that are most correlated with a measure of aneuploidy in
tumor samples. This led to a 70-gene signature referred to as
‘‘CIN70.’’ Indeed 31 of these 70 genes appear in Table 2
(P,10253). However, several top genes of the attractor, such as
CENPA, DLGAP5, KIF2C, BUB1 and CCNA2 are not present in the
CIN70 list. Mitotic CIN is increasingly recognized [21] as a
widespread multi-cancer phenomenon.
The attractor is characterized by overexpression of kinetochore-
associated genes, which is known [22] to induce CIN. Overex-
pression of several of the genes of the attractor, such as the top
gene CENPA [23], as well as MAD2L1 [24] and TPX2 [25], has
also been independently previously found associated with CIN.
Included in the mitotic CIN attractor are key components of
mitotic checkpoint signaling [26], such as BUB1B, MAD2L1 (aka
MAD2), CDC20, and TTK (aka MSP1). Also among the genes in
the attractor isMKI67 (aka Ki-67), which has been widely used as a
proliferation rate marker in cancer.
Among transcription factors, we found MYBL2 (aka B-Myb) and
FOXM1 to be strongly associated with the attractor. They are
already known to be sequentially recruited to promote late cell
cycle gene expression [27] to prepare for mitosis.
Inactivation of the retinoblastoma (RB) tumor suppressor
promotes CIN [28] and the expression of the attractor signature.
Indeed, a similar expression of a ‘‘proliferation gene cluster [29]’’
was found strongly associated with the human papillomavirus E7
oncogene, which abrogates RB protein function and activates
E2F-regulated genes. Consistently, many among the genes of the
attractor correspond to E2F pathway genes controlling cell
division or proliferation. Among the E2F transcription factors,
we found that E2F8 and E2F7 are most strongly associated with
the attractor.
Lymphocyte-Specific Attractor Metagene
This attractor consists mainly of lymphocyte-specific genes with
prominent presence of CD53, PTPRC, LAPTM5, DOCK2, LCP2
and IL10RA. It is strongly associated with the expression of
microRNA miR-142 as well as with particular hypermethylated
and hypomethylated gene signatures [30]. There is also significant
overlap between the sets of hypomethylated and overexpressed
genes, suggesting that their expression is triggered by hypomethy-
lation. Gene set enrichment analysis reveals that the attractor is
found enriched in genes known to be preferentially expressed in
differentiation into lymphocytes [31]. Table 3 provides a listing of
the top 100 genes of the lymphocyte-specific attractor based on
Table 2. Top 100 genes of the mitotic CIN attractor based on
six datasets.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
1 CENPA 0.720 51 CDCA8 0.532
2 DLGAP5 0.693 52 CDC45 0.528
3 MELK 0.684 53 KIF18A 0.524
4 BUB1 0.674 54 HMMR 0.506
5 KIF2C 0.660 55 TOP2A 0.505
6 KIF20A 0.658 56 CENPF 0.503
7 KIF4A 0.656 57 ZWINT 0.503
8 CCNA2 0.654 58 PLK1 0.501
9 CCNB2 0.652 59 RAD51AP1 0.501
10 NCAPG 0.649 60 FAM83D 0.498
11 TTK 0.642 61 E2F8 0.497
12 CEP55 0.638 62 CENPE 0.497
13 CCNB1 0.632 63 MKI67 0.492
14 CDK1 0.629 64 CENPN 0.491
15 HJURP 0.626 65 MAD2L1 0.489
16 CDC20 0.624 66 CHEK1 0.486
17 CDCA5 0.615 67 GTSE1 0.477
18 NCAPH 0.615 68 RAD51 0.475
19 BUB1B 0.609 69 SGOL2 0.474
20 KIF23 0.592 70 PARPBP 0.469
21 KIF11 0.591 71 TRIP13 0.467
22 BIRC5 0.589 72 SHCBP1 0.465
23 NUF2 0.587 73 DTL 0.465
24 TPX2 0.586 74 CENPL 0.462
25 AURKB 0.582 75 FEN1 0.461
26 RACGAP1 0.580 76 FANCI 0.461
27 NUSAP1 0.580 77 FBXO5 0.459
28 ASPM 0.579 78 ECT2 0.457
29 MCM10 0.579 79 MND1 0.456
30 PRC1 0.576 80 CDC25C 0.456
31 DEPDC1B 0.572 81 PBK 0.456
32 UBE2C 0.569 82 KPNA2 0.452
33 UBE2T 0.567 83 RAD54L 0.452
34 NEK2 0.566 84 ESPL1 0.447
35 FOXM1 0.565 85 CDCA2 0.446
36 NDC80 0.556 86 FAM64A 0.440
37 CDCA3 0.556 87 CENPK 0.436
38 FAM54A 0.553 88 MYBL2 0.435
39 ANLN 0.551 89 SPAG5 0.434
40 KIF15 0.548 90 EZH2 0.431
41 STIL 0.547 91 SMC4 0.430
42 EXO1 0.542 92 TACC3 0.428
43 AURKA 0.540 93 C11orf82 0.427
44 PTTG1 0.539 94 MASTL 0.426
45 OIP5 0.539 95 ASF1B 0.426
46 RRM2 0.539 96 PTTG3P 0.425
47 DEPDC1 0.539 97 CENPW 0.424
48 CDKN3 0.538 98 ORC1 0.424
49 KIF14 0.537 99 HELLS 0.422
Table 2. Cont.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
50 SPC25 0.534 100 TK1 0.421
doi:10.1371/journal.pcbi.1002920.t002
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their average mutual information (Materials and Methods) with
their corresponding attractor metagenes.
The gene membership of the attractor provides hints about the
underlying immune mechanism, which could be valuable towards
generating hypotheses for potential immunotherapies such as
adoptive transfer of lymphocytes. For example, the presence of the
signal-transducing LCP2 (aka SLP-76) gene, together with the
adaptor FYB (aka ADAP), suggests the formation of the SLP-76-
ADAP adaptor module, which is known to regulate lymphocyte
co-stimulation mediated by integrin ITGB2 (aka LFA-1), another
prominent gene in the attractor [32].
Association of the Three Main Attractor Metagenes with
Prognosis in Breast Cancer
We found that each of the above three main attractors under
particular conditions is highly prognostic in breast cancer by
analysing the METABRIC discovery breast cancer dataset [33]
which includes both expression as well as survival data.
Mesenchymal transition attractor. In breast cancer, the
mesenchymal transition attractor is expressed very early, as cancer
becomes invasive. The presence of the attractor in a particular
sample of high-stage tumor in not as informative, because of
heterogeneity. On the other hand we found that the presence of
the attractor in early-stage tumors is highly prognostic, consistent
with the hypothesis that it indicates increased invasiveness. As
shown in Figure 2, the Kaplan-Meier 15-year survival curves of
the mesenchymal transition attractor using all samples does not
show any significance. However, when we restrict the samples to
early stage patients, defined as having no positive lymph nodes and
tumor size less than 30 mm, the association between the attractor
and survival became significant (P=0.032).
Mitotic CIN attractor. The expression of the mitotic CIN
attractor indicates that the tumor is dividing uncontrollably and
therefore, in all cases, the attractor is highly prognostic for survival.
The corresponding Kaplan-Meier 15-year survival curve
(P,261028) is shown in Figure 3. Furthermore, we ranked all
the genes in terms of the concordance index [34] between the
survival and the individual gene’s expression value from the same
rich dataset. Table 4 shows the top 100 genes, within which 47
(indicated by underline and boldface), including the top six, are
also among the genes shown in Table 2 (P=2610298 by Fisher’s
exact test). This extraordinary enrichment (also note that eight
among the top ten genes, including the top three, are among the
genes of Table 2) demonstrates that the members of the mitotic
CIN attractor are, among all genes, the most prognostic ones, at
least in breast cancer.
Lymphocyte-specific attractor. We found the attractor to
be strongly protective in ER-negative breast cancers. As shown
in Figure 4, the Kaplan-Meier 15-year survival curve restricted
to ER-negative reveals association with longer survival
(P= 0.004). Although the precise underlying biological mech-
anisms are unclear, it appears that this effect is due to some
type of immune system recruitment to fight cancer. Interest-
ingly, however, this effect is reversed in the presence of
multiple positive lymph nodes. Indeed, the corresponding
Table 3. Top 100 genes of the lymphocyte-specific attractor
based on six datasets.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
1 PTPRC 0.782 51 NCF1 0.560
2 CD53 0.768 52 CCL5 0.557
3 LCP2 0.739 53 LST1 0.557
4 LAPTM5 0.708 54 CD3D 0.553
5 DOCK2 0.699 55 RCSD1 0.548
6 IL10RA 0.699 56 FGL2 0.538
7 CYBB 0.698 57 HCST 0.538
8 CD48 0.691 58 MARCH1 0.538
9 ITGB2 0.679 59 FERMT3 0.536
10 EVI2B 0.675 60 FCGR2B 0.533
11 MS4A6A 0.673 61 GIMAP5 0.530
12 TFEC 0.659 62 MYO1F 0.530
13 SLA 0.657 63 KLHL6 0.530
14 TNFSF13B 0.657 64 GIMAP1 0.527
15 C1orf162 0.656 65 CD163 0.524
16 SAMSN1 0.652 66 CLEC7A 0.522
17 PLEK 0.649 67 CCR1 0.518
18 GMFG 0.647 68 GBP5 0.517
19 GIMAP4 0.647 69 NCF2 0.516
20 SASH3 0.645 70 HLA-DPA1 0.516
21 EVI2A 0.638 71 RNASE6 0.515
22 SRGN 0.638 72 CD14 0.515
23 AIF1 0.636 73 FAM26F 0.511
24 LAIR1 0.627 74 CD4 0.510
25 FYB 0.625 75 FCGR1A 0.506
26 FCER1G 0.623 76 GZMA 0.506
27 MPEG1 0.621 77 GPR183 0.505
28 CD86 0.621 78 CD84 0.505
29 C3AR1 0.611 79 NKG7 0.504
30 C1QB 0.608 80 C1QA 0.502
31 CD2 0.606 81 CD300LF 0.500
32 HCLS1 0.599 82 FPR3 0.499
33 HCK 0.592 83 PARVG 0.496
34 MNDA 0.587 84 TRAF3IP3 0.494
35 CD37 0.587 85 TYROBP 0.492
36 LY96 0.585 86 LPXN 0.492
37 CCR5 0.585 87 GIMAP8 0.492
38 ARHGAP9 0.580 88 MS4A7 0.490
39 CD52 0.580 89 IL2RB 0.489
40 GPR65 0.580 90 CD300A 0.488
41 GIMAP6 0.578 91 IGSF6 0.488
42 SLAMF8 0.577 92 SELPLG 0.488
43 WIPF1 0.577 93 FCGR2A 0.487
44 MS4A4A 0.574 94 NCKAP1L 0.483
45 ARHGAP15 0.573 95 DOK2 0.483
46 HAVCR2 0.567 96 CD247 0.481
47 ARHGAP30 0.566 97 SELL 0.480
48 CLEC4A 0.566 98 GZMK 0.479
49 TAGAP 0.564 99 CCR2 0.479
Table 3. Cont.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
50 CYTIP 0.563 100 LY86 0.479
doi:10.1371/journal.pcbi.1002920.t003
Attractor Metagenes in Cancer
PLOS Computational Biology | www.ploscompbiol.org 6 February 2013 | Volume 9 | Issue 2 | e1002920
Kaplan-Meier curve shown on the right side of Figure 4 when
restricted to patients with more than five positive lymph nodes
demonstrates that the presence of the signature is associated
with bad prognosis. This reversal may be explained by the fact
that the presence of the lymphocyte-specific signature when
lymph nodes are already affected implies that the cancer has
obtained a (devastating for the patient) tolerance to this type of
immune system recruitment.
Other Attractors
Chr8q24.3 amplicon attractor. Amplification in chr8q24 is
often considered to be associated with cancer because of the
presence of the MYC (aka c-Myc) oncogene at location 8q24.21.
Indeed, MYC is one of 157 genes in ‘‘amplicon 8q23-q24’’
previously identified [35] in an extensive study of the breast cancer
‘‘amplicome’’ derived from 191 samples.
We found, however, that the core of the amplified genes occurs at
location 8q24.3 and this is, in fact, our most prominent multi-cancer
amplicon attractor. Core genes of the attractor are PUF60 (aka FIR),
EXOSC4, SHARPIN, HSF1, BOP1, SLC52A2. It is known that
PUF60 can repress c-Myc via its far upstream element (FUSE),
although a particular isoform was found to have the opposite effect
[36]. The other genes may also play important roles. For example,
HSF1 (heat shock transcription factor 1) has been associated with
cancer in various ways [37]. It was found [38] that HSF1 can induce
genomic instability through direct interaction with CDC20, a key
gene of the mitotic CIN attractor mentioned above (listed in
Table 2). Furthermore, HSF1 was found [39] required for the cell
transformation and tumorigenesis induced by the ERBB2 (aka
HER2) oncogene (see subsequent discussion of HER2 amplicon)
responsible for aggressive breast tumors.
The top ten genes of the chr8q24.3 attractor, ranked by the
average of the highest five values of mutual information (Materials
and Methods), are shown in Table 5. Interestingly, as shown in
one of the attractors in Supplementary Table S1, an aneuploidy
attractor involving a whole arm amplification of chr8q is also
occasionally present in multiple cancer types, and this 8q whole
arm amplification is the most prominent such aneuploidy attractor
among all chromosomes.
Furthermore, prognostic associations involving the 8q24.3
amplicon have recently been recognized in various cancers [40,41].
Figure 3. Kaplan-Meier curve of mitotic CIN attractor metagene
in breast cancer dataset. To evaluate the association between the
mitotic CIN metagene expression and the 15-year survival, patients
were divided into two groups: high mitotic CIN and low mitotic CIN.
This binary expression level was determined by whether the mitotic CIN
metagene expression value exceeding the mean of the patients. The P
value of the association based on log-rank test is 1.861028.
doi:10.1371/journal.pcbi.1002920.g003
Figure 2. Kaplan-Meier curve of mesenchymal transition attractor metagenes in breast cancer dataset. The mesenchymal transition
attractor metagene is most prominent in the early stage of breast cancer. The survival curve of the full dataset is insignificant (left). However, when
the samples are restricted to only those at early stage (with no positive lymph nodes and tumor size less than 30 mm), the association between the
mesenchymal transition attractor and the survival becomes significant (right), with P=0.032.
doi:10.1371/journal.pcbi.1002920.g002
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Table 4. List of top-ranked genes in terms of survival concordance index of the METABRIC discovery dataset demonstrating
enrichment of the mitotic CIN attractor.
Rank Gene Symbol Concordance Index Rank Gene Symbol Concordance Index
1 CDCA5 0.670 51 PRR11 0.639
2 AURKA 0.663 52 LOC651816 0.638
3 KIF20A 0.662 53 KRT80 0.638
4 TROAP 0.661 54 C15orf42 0.637
5 UBE2C 0.659 55 SGOL1 0.637
6 AURKA 0.658 56 GPI 0.637
7 FAM83D 0.657 57 CEP55 0.637
8 SHMT2 0.655 58 MCM10 0.636
9 UBE2C 0.655 59 PKMYT1 0.635
10 CCNB2 0.653 60 CENPN 0.635
11 TPX2 0.653 61 C20orf24 0.635
12 EXO1 0.653 62 SPC24 0.635
13 ORC6 0.653 63 RIPK4 0.635
14 CENPA 0.653 64 TOMM40 0.634
15 C1orf106 0.652 65 ANLN 0.634
16 GTSE1 0.652 66 ADRM1 0.634
17 MELK 0.651 67 NCAPG 0.633
18 STIP1 0.651 68 CDCA8 0.633
19 SPC25 0.649 69 AIF1L 0.633
20 CENPA 0.649 70 MRPS5 0.633
21 GARS 0.649 71 GPR56 0.633
22 MELK 0.649 72 PEX13 0.633
23 UCK2 0.648 73 ENO1 0.633
24 HJURP 0.648 74 NUTF2 0.633
25 PTTG1 0.647 75 MEMO1 0.632
26 CBX2 0.646 76 TXNRD1 0.632
27 CCNE1 0.646 77 SLC7A5 0.631
28 PLK1 0.646 78 FOXM1 0.631
29 KIF2C 0.645 79 KIF14 0.631
30 CCNA2 0.645 80 PPP1R14B 0.631
31 GMPSP1 0.645 81 FAM54A 0.630
32 AURKB 0.645 82 C20orf24 0.630
33 BUB1 0.644 83 SGOL1 0.630
34 TRIP13 0.643 84 NUP93 0.630
35 FOXM1 0.643 85 ZNF695 0.630
36 CDC20 0.643 86 BIRC5 0.630
37 LOC731049 0.642 87 CENPL 0.630
38 POLQ 0.642 88 SOX11 0.630
39 GSK3B 0.642 89 KIF23 0.629
40 CCNE1 0.642 90 SLC52A2 0.629
41 KIF4A 0.641 91 AIF1L 0.629
42 PRC1 0.641 92 FEN1 0.629
43 LAD1 0.641 93 CDC25A 0.629
44 FAM64A 0.641 94 CDCA3 0.628
45 SAPCD2 0.641 95 TMEM132A 0.628
46 RACGAP1 0.641 96 CENPE 0.628
47 POLR2D 0.641 97 NACC2 0.628
48 CKAP2L 0.640 98 TTK 0.628
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Chr17q12 HER2 amplicon attractor. This amplicon is
prominent in breast cancer [42] and we also found it present in
some samples of ovarian cancer, but not as much in colon cancer.
So we initially used the four datasets of breast and ovarian cancer
for deriving the attractor. We found that ERBB2 (aka HER2),
STAR3, GRB7 and PGAP3 were the top-ranked genes, consistent
with their known presence in the amplicon. We also found that
gene MIEN1 (aka C17orf37) was very highly ranked in the two
datasets in which its probe set was present. MIEN1 has recently
been identified as an important gene within the 17q12 amplicon in
various cancers including prostate cancer [43]. Therefore, we
augmented the choice of datasets to the following seven, of which
MIEN1 is included in five: breast GSE2034, breast GSE32646,
breast GSE36771, breast TCGA, ovarian GSE9891, ovarian
GSE26193, ovarian TCGA. Table 5 shows the top ten genes
ranked by the average of the top five scores of mutual information
(Materials and Methods) in the seven datasets for each gene. The
results suggest that the above-mentioned five genes, including
MIEN1, are consistently strongly co-expressed, and therefore are
likely ‘‘driver’’ genes in the amplicon.
In addition to the narrow HER2 amplicon, it is known that
sometimes a large amplicon extends to more than a million bases
containing both HER2 as well as TOP2A (one of the genes of the
mitotic CIN attractor) at 17q21 [44].We have observed thatTOP2A
indeed appears among the top 50 genes in terms of its association
with the attractor in breast cancer. HER2/TOP2A co-amplification
has been linked with better clinical response to therapy.
Estrogen receptor breast cancer attractor. We found this
attractor clearly present only in breast cancer, and therefore we
derived it using six breast cancer datasets (GSE2034, GSE3494,
GSE31448, GSE32646, GSE36771, breast TCGA). Table 6
shows the top 50 genes ranked by the average mutual information
(Materials and Methods) in these datasets, revealing that genes
AGR3, CA12, AGR2, GATA3, FOXA1, MLPH and TBC1D9 are
strongly co-expressed with the estrogen receptor ESR1 in the
attractor. However, this co-expression is not as uniform as in the
other attractors. For example, the progesterone receptor PGR
appear in the list, but in reality it can be underexpressed even if the
estrogen receptor ESR1 is not.
Comparison with Other Unsupervised Algorithms
The scope of the algorithm identifying attractor metagenes is
different from that of other unsupervised methods, which are
usually aimed at identifying subtypes or mutually exclusive
clusters. Nevertheless, it is interesting to find to what extent other
algorithms can produce multiple cancer signatures each of which
appears in nearly identical form across different types. We applied
three widely used methods, k-means clustering, principal component
Figure 4. Kaplan-Meier curve of lymphocyte-specific attractor metagenes in breast cancer dataset. For ER-negative patients, the
expression of the attractor is highly protective (high expression implies longer survival, left). However, when multiple lymph nodes are already
affected, the expression of the attractor has a reversed effect on survival. When we restrict the samples to those with more than five positive lymph
nodes, higher expression of the lymphocyte-specific attractor implies shorter survival (right), although the association is not significant due to the
limited number of samples (76).
doi:10.1371/journal.pcbi.1002920.g004
Table 4. Cont.
Rank Gene Symbol Concordance Index Rank Gene Symbol Concordance Index
49 PTTG1 0.640 99 SNRPA1 0.628
50 ECE2 0.639 100 MMP15 0.628
The 47 underlined genes are also among the top 100 genes of the mitotic CIN attractor (Table 2).
doi:10.1371/journal.pcbi.1002920.t004
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analysis and hierarchical clustering on the six cancer datasets used in
this paper. In all cases, we listed the top fifty genes in each cluster and
applied the same clustering algorithm as in the main text to find
common genes among them and group them together. The results
are shown in Supplementary Text S2 and Supplementary Tables S5,
S6, S7. We found that, in all cases, these well-established methods
cannot identify multiple universal metagenes common in all six
tested datasets.
Using Attractor Metagenes as Proxies of Biomolecular
Events
A biomolecular event, whether it is present in multiple cancer
types or it is cancer specific, can be represented by a ‘‘consensus
attractor metagene’’ after analyzing multiple datasets. To generate
such consensus attractors, we use genes that were profiled by at
least three of the six datasets, then rank individual genes in terms
of their average mutual information (Materials and Methods) with
the corresponding attractor metagenes across all datasets in which
the gene was profiled.
For example, Figure 5 contains scatter plots from four different
rich breast cancer datasets connecting the mitotic CIN and
estrogen receptor attractors. It has previously been reported [45]
that breast tumors with high chromosomal instability are
predominantly of the estrogen receptor negative phenotype.
Although these scatter plots cannot be used for precise conclusions,
they do suggest in all cases that ER-negative tumors have high
mitotic chromosomal instability (or equivalently that low chromo-
somal instability implies that the tumor is ER-positive). The
reverse relationship, however, is not as clear.
Discussion
Gene expression analysis has resulted in several cancer types
being further classified into subtypes labeled, e.g. as ‘‘mesenchy-
mal’’ or ‘‘proliferative.’’ Such characterizations, however, may
sometimes simply reflect the presence of the mesenchymal
transition attractor or the mitotic chromosomal instability
attractor, respectively, in some of the analyzed samples. Similar
subtype characterizations across cancer types often share several
common genes, but the consistency of these similarities has not
been significantly high.
By contrast, using an unconstrained algorithm independent of
subtype classification or dimensionality reduction, we identified
several attractors exhibiting remarkable consistency across many
cancer types, suggesting that each of them represents a precise
biological phenomenon present in multiple cancers.
We found that the mesenchymal transition attractor is
significantly present only in samples whose stage designation has
exceeded a threshold, but not in all of such samples. On the other
hand, the absence of the mesenchymal transition attractor in a
profiled high-stage sample (or the absence of the mitotic
chromosomal instability attractor in a profiled high-grade sample)
does not necessarily mean that the attractor is not present in other
locations of the same tumor. Indeed, it is increasingly appreciated
[46] that tumors are highly heterogeneous. Therefore it is possible
for the same tumor to contain components, in which, e.g., some
are migratory having undergone mesenchymal transition, some
other ones are highly proliferative, etc. If so, attempts for subtype
classification based on one particular site in a sample may be
confusing.
Existing molecular marker products make use of multigene
assays that have been derived from phenotypic associations in
particular cancer types. For breast cancer, biomarkers such as
Oncotype DX [47] and Mammaprint [48] contain several genes
highly ranked in our attractors. For example, most of the genes
used for the Oncotype DX breast cancer recurrence score directly
converge to one of our identified attractors: MMP11 to the
mesenchymal transition attractor; MKI67 (aka Ki-67), AURKA (aka
STK15), BIRC5 (aka Survivin), CCNB1, and MYBL2 to the mitotic
CIN attractor; CD68 to the lymphocyte-specific attractor; ERBB2
and GRB7 to the HER2 amplicon attractor; and ESR1, SCUBE2,
PGR to the estrogen receptor attractor.
We envision, instead, a multi-cancer biomarker product that will
include detection of the level of expression of each of the key attractor
metagenes. These levels would need to be combined in different ways
in different cancer types, but each of the metagenes would indicate
the same attribute and the contributions of each component will be
cleanly distinguished. Even though molecular marker genes in some
existing products are already separated into groups that are related to
our attractor designation, any improvement in diagnostic, prognostic,
or predictive accuracy resulting from better such group designation
and better choice of genes in each group would be highly desirable.
Table 5. List of top ten genes in the chr8q24.3 and HER2 amplicons.
chr8q24.3 HER2
Rank Gene Symbol
Avg MI of Top 4
Datasets Rank Gene Symbol
Avg MI of Top 4
Datasets
1 EXOSC4 0.716 1 PGAP3 0.794
2 PUF60 0.659 2 ERBB2 0.793
3 BOP1 0.653 3 STARD3 0.768
4 SLC52A2 0.639 4 MIEN1 0.764
5 SHARPIN 0.634 5 GRB7 0.718
6 HSF1 0.616 6 PSMD3 0.602
7 FBXL6 0.615 7 GSDMB 0.539
8 CYC1 0.608 8 ORMDL3 0.498
9 SCRIB 0.552 9 MED24 0.414
10 GPAA1 0.551 10 MED1 0.400
doi:10.1371/journal.pcbi.1002920.t005
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We hope that the identification of the attractors of cancer, as
presented here, will be valuable in that regard.
Materials and Methods
The full code of the attractor finding algorithm is publicly
available in the Sage Bionetworks Synapse platform at https://
synapse.sagebase.org/#Synapse:syn1446295. In addition, we
provide a pseudo-code in Supplementary Text S3.
General Attractor Finding Algorithm
We chose the association measure J(Gi,Gj) between genes to be a
power function with exponent a of a normalized estimated
information theoretic measure of the mutual information [49]
I(Gi,Gj) with minimum value 0 and maximum value 1 (see
‘‘Mutual information estimation’’ below; more sophisticated related
association measures [50] can also be used, but computational
complexity will be prohibitive). In other words, J(Gi,Gj)~
Ia(Gi,Gj), in which the exponent acan be any nonnegative number.
The value of I(Gi,Gj) is set to zero if the Pearson correlation
between the two genes is negative. Each iteration defines a new
metagene in which the weightwi for gene Gi is equal to
wi~J(Gi,M) where M is the immediately preceding metagene.
The process is repeated until the magnitude of the difference
between two consecutive weight vectors is less than a threshold,
which we chose to be equal to 1027.
At one extreme, if a is sufficiently large then each of the seeds
will create its own single-gene attractor because all other genes will
always have near-zero weights. In that case, the total number of
attractors will be equal to the number of genes. At the other
extreme, if a is zero then all weights will remain equal to each
other representing the average of all genes, so there will only be
one attractor. The higher the value of a, the ‘‘sharper’’ (more
focused on its top gene) each attractor will be and the higher the
total number of attractors will be. As the value of a is gradually
decreased, the attractor from a particular seed will transform itself,
occasionally in a discontinuous manner, thus providing insight into
potential related biological mechanisms.
We empirically found that an appropriate choice of a (in the
sense of maximizing the strength of the attractor, as defined below)
for general attractors is around 5, in which case there will typically
be approximately 50 to 150 resulting attractors, each resulting
from many attractee genes. An alternative to the power function
can be a sigmoid function with varying steepness, but we found
that the consistency of the resulting attractors was worse in that
case.
As mentioned in the Introduction, an attractor metagene can
also be interpreted as a set of the top genes of the attractor, i.e., a
gene set that includes only the genes that are significantly
associated with the attractor. One empirical choice for such a
gene set would be to include only the genes whose mutual
information (or the z-score thereof) with the attractor metagene
exceeds a particular threshold. In fact, the attractor finding
algorithm itself can be designed to discover ‘‘attractor gene sets,’’
without assigning weights to genes. In that case, metagenes are
defined as simple averages of the genes in a gene set, and each
iteration leads to a new gene set consisting of the new set of top-
ranked genes in terms of their association with the previous
metagene (gene set sizes can be constant or adaptively changing in
various ways). We found, however, that such a method has the
disadvantage of occasionally leading to attractors with significant
overlap, which requires additional post-processing steps.
Identified attractors can be ranked in various ways. The
‘‘strength of an attractor’’ can be defined as the mutual
information between the nth top gene of the attractor and the
attractor metagene. Indeed, if this measure is high, this implies
that at least the top n genes of the attractor are strongly co-
expressed. We selected n=10 as a reasonable choice, not too large,
but sufficiently so to represent a real complex biological
phenomenon of co-expression of at least ten genes. For amplicons,
n=5 is sufficient to ensure that the oncogenes are included in the
co-expression). We use these choices when referring to the strength
of an attractor.
The top genes of many among the found attractors are
genomically localized. In that case the biomolecular event that
they represent is often the presence of a particular copy number
variation. In the cancer datasets that we tried, this phenomenon
almost always corresponds to a local amplification event known as
an amplicon. We therefore also devised a related amplicon-finding
algorithm, custom-designed to identify localized amplicon-repre-
senting attractor metagenes, described below.
Genomically Localized Attractor Finding Algorithm
To identify genomically localized attractors – almost always
amplicons – we use the same algorithm but for each seed gene we
restrict the set of candidate attractor genes to only include those in
the local genomic neighbourhood of the gene, and we optimize the
exponent a so that the strength of the attractor is maximized.
Specifically, we sort the genes in each chromosome in terms of
their genomic location and we only consider the genes within a
Table 6. Top 50 genes of the estrogen receptor breast cancer
attractor.
Rank Gene Symbol Avg MI Rank Gene Symbol Avg MI
1 AGR3 0.847 26 ERBB4 0.393
2 CA12 0.616 27 AR 0.383
3 FOXA1 0.613 28 P4HTM 0.383
4 GATA3 0.585 29 SLC44A4 0.380
5 MLPH 0.580 30 KDM4B 0.375
6 AGR2 0.570 31 GFRA1 0.374
7 ESR1 0.543 32 MAPT 0.370
8 TBC1D9 0.540 33 MYB 0.364
9 XBP1 0.460 34 DACH1 0.359
10 ANXA9 0.456 35 SLC7A8 0.359
11 PRR15 0.452 36 MAGED2 0.358
12 SCUBE2 0.444 37 FBP1 0.357
13 FSIP1 0.438 38 SLC22A5 0.355
14 TFF3 0.429 39 CMBL 0.346
15 SPDEF 0.429 40 DYNLRB2 0.346
16 NAT1 0.428 41 C6orf211 0.342
17 ABAT 0.423 42 GREB1 0.342
18 CCDC170 0.422 43 SIDT1 0.338
19 DNALI1 0.418 44 TTC39A 0.330
20 DEGS2 0.415 45 FAM214A 0.326
21 DNAJC12 0.411 46 IL6ST 0.324
22 SLC39A6 0.406 47 CXXC5 0.323
23 CAPN8 0.399 48 ACADSB 0.323
24 TFF1 0.397 49 CELSR1 0.322
25 THSD4 0.395 50 CLSTN2 0.322
doi:10.1371/journal.pcbi.1002920.t006
Attractor Metagenes in Cancer
PLOS Computational Biology | www.ploscompbiol.org 11 February 2013 | Volume 9 | Issue 2 | e1002920
window of size 51, i.e., with 25 genes on each side of the seed gene.
We further optimize the choice of the exponent a for each seed, by
allowing a to range from 1.0 to 6.0 with step size of 0.5 and
selecting the attractor with the highest strength.
Because the set of allowed genes is different for each seed, the
attractors will be different from each other, but ‘‘neighbouring’’
attractors will usually be very similar to each other. Therefore,
following exhaustive attractor finding from each seed gene in a
chromosome, we apply a filtering algorithm to only select the
highest-strength attractor in each local genomic region, as follows:
For each attractor, we rank all the genes in terms of their mutual
information with the corresponding attractor metagene and we
define the range of the attractor to be the chromosomal range of
its top 15 genes. If there is any other attractor with overlapping
range and higher strength, then the former attractor is filtered out.
This filtering is done in parallel, so elimination of attractors occurs
simultaneously.
Mutual Information Estimation
Assuming that the continuous expression levels of two genes G1
and G2 are governed by a joint probability density p12 with
corresponding marginal p1 and p2, the mutual information
I(G1,G2) is defined as the expected value of log(p12=p1p2). It is
a non-negative quantity representing the information that each
Figure 5. Scatter plots demonstrating the relationship between mitotic CIN attractor and estrogen receptor attractor in breast
cancer. The two metagenes were defined to be ‘‘consensus attractors’’ after ranking individual genes in terms of their average mutual information
with the corresponding attractor metagenes, across all datasets, and selecting the genes having average mutual information greater than 0.5. These
criteria led to 59 genes in the consensus mitotic CIN attractor (the top 59 genes in Table 2), and AGR3, ESR1, CA12, AGR2, GATA3, FOXA1, MLPH and
TBC1D9 (the top eight genes in Table 6) in the consensus estrogen receptor breast cancer attractor. These scatter plots reveal that ER-negative breast
tumors have high mitotic chromosomal instability, but not necessarily vice versa.
doi:10.1371/journal.pcbi.1002920.g005
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one of the variables provides about the other. The pairwise mutual
information has successfully been used as a general measure of the
correlation between two random variables. We compute mutual
information with a spline-based estimator [51] using six bins in
each dimension. This method divides the observation space into
equally spaced bins and blurs the boundaries between the bins
with spline basis functions using third-order B-splines. We further
normalize the estimated mutual information by dividing by the
maximum of the estimated I(G1,G1) and I(G2,G2), so the
maximum possible value of I(G1,G2) is 1.
Pre-processing Gene Expression Datasets
We used Level 3 data when directly available, and imputed
missing values using a k-nearest-neighbour algorithm with k= 10,
as implemented in R [52]. We normalized the other datasets on
the Affymetrix platform using the RMA algorithm as implemented
in the affy package in Bioconductor [53]. To avoid biasing
attractor convergence with multiple correlated probe sets of the
same gene, we summarized the probe set-level expression values
into the gene-level expression values by taking the mean of the
expression values of probe sets for the same genes. We used the
annotations for the probe sets given in the jetset package [54].
To investigate the associations between the attractor metagene
expression and the tumor stage and grade, we used the following
annotated gene expression datasets. For stage association: Breast
(GSE3893), TCGA Ovarian, Colon (GSE14333). For grade
association: Breast (GSE3494), TCGA Ovarian, Bladder
(GSE13507). For Breast GSE3494 we used only the samples
profiled by U133A arrays. For Breast GSE3893 we combined two
platforms by taking the intersections of the probes in the U133A
and the U133Plus 2.0 arrays. For datasets profiled by Affymetrix
platforms all the datasets were normalized using the RMA
algorithm. For Bladder GSE13507 normalization was done as
provided in the GEO.
P Value Evaluation
P values for gene set enrichment were evaluated with the
cumulative hypergeometric distribution using the total number of
genes in each dataset.
The significance of the consistency of the mesenchymal
transition and mitotic CIN attractors was evaluated as follows:
Supplementary Table S1 contains 210 gene sets from six cancer
datasets. Each of the gene sets contains 50 genes. The
mesenchymal transition metagene has eight genes (COL5A2,
COL1A2, SPARC, CTSK, FBN1, VCAN, AEBP1, SERPINF1)
common across all six datasets. The mitotic CIN metagene has 13
common genes (CENPA, DLGAP5, KIF2C, CCNB2, MELK,
CCNA2, KIF20A, HJURP, NUSAP1, BUB1, TTK, KIF11,
NCAPH) across all six datasets. To evaluate the significance of the
consistency across the six datasets, we randomly generated 210
gene sets with the same sizes as those in the Table. In other words,
we randomly selected 50 genes out of the 11,395 common genes to
generate a random gene set. We created 210 such random gene
sets, and then assigned them to six different datasets according to
the settings in the Table. We then performed the clustering
algorithm described in Materials and Methods. Each time, we
counted the maximum number of genes common in all six
datasets, and we repeated this process ten million times. This
constitutes a conservative way of evaluating consistency, in the
sense that for each random experiment we only record the
maximum number of common genes in the gene set cluster, and
we created random gene sets using only the common genes in the
six datasets. In these ten million experiments, it never occurred
that more than one gene was common in all six datasets.
Therefore, the corresponding P value for both the mesenchymal
transition metagene as well as the mitotic CIN metagene is less
than 1027, and is in fact much lower than that given the large
number (8 and 13 respectively) of the common genes.
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hierarchical clustering.
(XLS)
Text S1 Datasets and methods used to derive Supplementary
Tables S1, S2, S3, S4.
(DOCX)
Text S2 Comparison with other unsupervised algorithms.
(DOCX)
Text S3 Pseudo-code for attractor metagene finding algorithm.
(DOCX)
Acknowledgments
We thank the Chang Gung Memorial Hospital-Linkou and Chang Gung
University, Taoyuan, Taiwan, R.O.C. and in particular their Head and
Neck Oncology Group and Dr. Tzu-Chen Yen who served as our contact
point, for providing us with survival data for dataset GSE25104.
This study makes use of data generated by the Molecular Taxonomy of
Breast Cancer International Consortium. Funding for that project was
provided by Cancer Research UK and the British Columbia Cancer
Agency Branch. Our results using these data (the METABRIC 996-sample
discovery dataset) were produced during our participation in the Sage
Bionetworks/DREAM breast cancer prognosis Challenge.
Author Contributions
Conceived and designed the experiments: WYC THOY DA. Performed
the experiments: WYC THOY DA. Analyzed the data: WYC THOY DA.
Contributed reagents/materials/analysis tools: WYC THOY DA. Wrote
the paper: WYC DA.
Attractor Metagenes in Cancer
PLOS Computational Biology | www.ploscompbiol.org 13 February 2013 | Volume 9 | Issue 2 | e1002920
References
1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
2. Nevins JR, Potti A (2007) Mining gene expression profiles: expression signatures
as cancer phenotypes. Nat Rev Genet 8: 601–609.
3. Segal E, Friedman N, Kaminski N, Regev A, Koller D (2005) From signatures to
models: understanding cancer using microarrays. Nat Genet 37 Suppl: S38–45.
4. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, et al. (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to
therapy. Nat Med 17: 500–503.
5. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated
genomic analysis identifies clinically relevant subtypes of glioblastoma charac-
terized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:
98–110.
6. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of
ovarian carcinoma. Nature 474: 609–615.
7. Brunet JP, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular
pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 101:
4164–4169.
8. Monti S, Tamayo P, Mesirov J, Golub T (2003) Consensus clustering: A
resampling-based method for class discovery and visualization of gene expression
microarray data. Machine Learning 52: 91–118.
9. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of
proliferation. Nat Rev Cancer 6: 99–106.
10. Kim H, Watkinson J, Varadan V, Anastassiou D (2010) Multi-cancer
computational analysis reveals invasion-associated variant of desmoplastic
reaction involving INHBA, THBS2 and COL11A1. BMCMed Genomics 3: 51.
11. Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, et al. (2011)
Human cancer cells express Slug-based epithelial-mesenchymal transition gene
expression signature obtained in vivo. BMC Cancer 11: 529.
12. Cheng WY, Kandel JJ, Yamashiro DJ, Canoll P, Anastassiou D (2012) A multi-
cancer mesenchymal transition gene expression signature is associated with
prolonged time to recurrence in glioblastoma. PLoS One 7: e34705.
13. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A
stroma-related gene signature predicts resistance to neoadjuvant chemotherapy
in breast cancer. Nat Med 15: 68–74.
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell 133:
704–715.
15. Hay ED (1995) An overview of epithelio-mesenchymal transformation. Acta
Anat (Basel) 154: 8–20.
16. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat
Rev Cancer 2: 442–454.
17. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition.
J Clin Invest 119: 1420–1428.
18. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, et al. (2010) TWISTing
stemness, inflammation and proliferation of epithelial ovarian cancer cells
through MIR199A2/214. Oncogene 29: 3545–3553.
19. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression
profiling in breast cancer: understanding the molecular basis of histologic grade
to improve prognosis. J Natl Cancer Inst 98: 262–272.
20. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of
chromosomal instability inferred from gene expression profiles predicts clinical
outcome in multiple human cancers. Nat Genet 38: 1043–1048.
21. Schvartzman JM, Sotillo R, Benezra R (2010) Mitotic chromosomal instability
and cancer: mouse modelling of the human disease. Nat Rev Cancer 10: 102–
115.
22. Yuen KW, Montpetit B, Hieter P (2005) The kinetochore and cancer: what’s the
connection? Curr Opin Cell Biol 17: 576–582.
23. Amato A, Schillaci T, Lentini L, Di Leonardo A (2009) CENPA overexpression
promotes genome instability in pRb-depleted human cells. Mol Cancer 8: 119.
24. Sotillo R, Schvartzman JM, Socci ND, Benezra R (2010) Mad2-induced
chromosome instability leads to lung tumour relapse after oncogene withdrawal.
Nature 464: 436–440.
25. Heidebrecht HJ, Adam-Klages S, Szczepanowski M, Pollmann M, Buck F, et al.
(2003) repp86: A human protein associated in the progression of mitosis. Mol
Cancer Res 1: 271–279.
26. Orr-Weaver TL, Weinberg RA (1998) A checkpoint on the road to cancer.
Nature 392: 223–224.
27. Sadasivam S, Duan S, DeCaprio JA (2012) The MuvB complex sequentially
recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 26:
474–489.
28. Manning AL, Dyson NJ (2012) RB: mitotic implications of a tumour suppressor.
Nat Rev Cancer 12: 220–226.
29. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, et al. (2005) Identification
of a proliferation gene cluster associated with HPV E6/E7 expression level and
viral DNA load in invasive cervical carcinoma. Oncogene 24: 7094–7104.
30. Andreopoulos B, Anastassiou D (2012) Integrated Analysis Reveals hsa-miR-142
as a Representative of a Lymphocyte-Specific Gene Expression and Methylation
Signature. Cancer Inform 11: 61–75.
31. Lee MS, Hanspers K, Barker CS, Korn AP, McCune JM (2004) Gene
expression profiles during human CD4+ T cell differentiation. Int Immunol 16:
1109–1124.
32. Wang H, Wei B, Bismuth G, Rudd CE (2009) SLP-76-ADAP adaptor module
regulates LFA-1 mediated costimulation and T cell motility. Proc Natl Acad
Sci U S A 106: 12436–12441.
33. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The
genomic and transcriptomic architecture of 2,000 breast tumours reveals novel
subgroups. Nature 486: 346–352.
34. Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in
survival analysis: model specific population value and confidence interval
estimation. Stat Med 23: 2109–2123.
35. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, et al. (2008)
Genome-wide functional synergy between amplified and mutated genes in
human breast cancer. Cancer Res 68: 9532–9540.
36. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, et al. (2006) An
essential role of alternative splicing of c-myc suppressor FUSE-binding protein-
interacting repressor in carcinogenesis. Cancer Res 66: 1409–1417.
37. Dai C, Whitesell L, Rogers AB, Lindquist S (2007) Heat shock factor 1 is a
powerful multifaceted modifier of carcinogenesis. Cell 130: 1005–1018.
38. Lee YJ, Lee HJ, Lee JS, Jeoung D, Kang CM, et al. (2008) A novel function for
HSF1-induced mitotic exit failure and genomic instability through direct
interaction between HSF1 and Cdc20. Oncogene 27: 2999–3009.
39. Meng L, Gabai VL, Sherman MY (2010) Heat-shock transcription factor HSF1
has a critical role in human epidermal growth factor receptor-2-induced cellular
transformation and tumorigenesis. Oncogene 29: 5204–5213.
40. Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, et al. (2012) Amplified
Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast
Cancers. PLoS One 7: e38575.
41. Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, et al. (2011) A novel
molecular signature identified by systems genetics approach predicts prognosis in
oral squamous cell carcinoma. PLoS One 6: e23452.
42. Theillet C (2010) What do we learn from HER2-positive breast cancer genomic
profiles? Breast Cancer Res 12: 107.
43. Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, et al. (2009) Novel
gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate
cancer cells. Oncogene 28: 2860–2872.
44. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, et al. (2008) Genomic
analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell
lines. Lab Invest 88: 491–503.
45. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, et al. (2011)
Paradoxical relationship between chromosomal instability and survival outcome
in cancer. Cancer Res 71: 3447–3452.
46. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012)
Intratumor heterogeneity and branched evolution revealed by multiregion
sequencing. N Engl J Med 366: 883–892.
47. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to
predict recurrence of tamoxifen-treated, node-negative breast cancer.
N Engl J Med 351: 2817–2826.
48. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene
expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–
536.
49. Cover TM, Thomas JA (2006) Elements of information theory. Hoboken, N.J.:
Wiley-Interscience. xxiii, 748 p.
50. Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, et al. (2011)
Detecting novel associations in large data sets. Science 334: 1518–1524.
51. Daub CO, Steuer R, Selbig J, Kloska S (2004) Estimating mutual information
using B-spline functions–an improved similarity measure for analysing gene
expression data. BMC Bioinformatics 5: 118.
52. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing
value estimation methods for DNA microarrays. Bioinformatics 17: 520–525.
53. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy–analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20: 307–315.
54. Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC (2011) Jetset: selecting the
optimal microarray probe set to represent a gene. BMC Bioinformatics 12: 474.
Attractor Metagenes in Cancer
PLOS Computational Biology | www.ploscompbiol.org 14 February 2013 | Volume 9 | Issue 2 | e1002920
